Literature DB >> 22809665

Inflammation-induced dysfunction of the low-density lipoprotein receptor-related protein-1 at the blood-brain barrier: protection by the antioxidant N-acetylcysteine.

Michelle A Erickson1, Kim Hansen, William A Banks.   

Abstract

Impairment in two blood-brain barrier (BBB) efflux transporters, p-glycoprotein (Pgp) and low-density lipoprotein receptor-related protein-1 (LRP-1) are thought to contribute to the progression of Alzheimer's disease (AD) by resulting in the brain accumulation of their substrate amyloid beta peptide (Aβ). The initial cause of impaired efflux, however, is unknown. We have shown that induction of systemic inflammation by intraperitoneal administration of lipopolysaccharide impairs the efflux of Aβ from the brain, suggesting that systemic inflammation could be one such initiator. In this study, we determined whether pre-administration of the antioxidant N-aceytlcysteine (Nac) has a protective effect against LPS-induced Aβ transporter dysfunction. Our findings were that Nac protected against LPS-induced Aβ transport dysfunction at the BBB through an LRP-1-dependent and Pgp-independent mechanism. This was associated with Nac exerting antioxidant effects in the periphery but not the brain, despite an increased rate of entry of Nac into the brain following LPS. We also found that Nac pre-administration resulted in lower blood levels of the cytokines and chemokines interferon-γ, interleukin-10, CCL2, CCL4, and CCL5, but only lowered CCL4 in the cerebral cortex and hippocampus. Finally, we observed that hippocampal cytokine responses to LPS were decreased compared to cortex. These findings demonstrate a novel mechanism by which antioxidants prevent Aβ accumulation in the brain caused by inflammation, and therefore protect against AD.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22809665      PMCID: PMC3434291          DOI: 10.1016/j.bbi.2012.07.003

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  73 in total

1.  Potential in vivo amelioration by N-acetyl-L-cysteine of oxidative stress in brain in human double mutant APP/PS-1 knock-in mice: toward therapeutic modulation of mild cognitive impairment.

Authors:  Quanzhen Huang; Christopher D Aluise; Gururaj Joshi; Rukhsana Sultana; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-09       Impact factor: 4.164

2.  Protective effect of N-acetyl-L-cysteine on amyloid beta-peptide-induced learning and memory deficits in mice.

Authors:  Ai-Ling Fu; Zhao-Hui Dong; Man-Ji Sun
Journal:  Brain Res       Date:  2006-07-26       Impact factor: 3.252

3.  Oxidative stress activates protein tyrosine kinase and matrix metalloproteinases leading to blood-brain barrier dysfunction.

Authors:  James Haorah; Servio H Ramirez; Kathy Schall; Daniel Smith; Rita Pandya; Yuri Persidsky
Journal:  J Neurochem       Date:  2007-01-23       Impact factor: 5.372

4.  Tong Luo Jiu Nao injection, a traditional Chinese medicinal preparation, inhibits MIP-1β expression in brain microvascular endothelial cells injured by oxygen-glucose deprivation.

Authors:  Jun Wang; Peng-Tao Li; Huan Du; Jin-Cai Hou; Wei-Hong Li; Yan-Shu Pan; Hui-Cong Chen
Journal:  J Ethnopharmacol       Date:  2012-02-17       Impact factor: 4.360

5.  Impact of p-glycoprotein inhibition and lipopolysaccharide administration on blood-brain barrier transport of colistin in mice.

Authors:  Liang Jin; Jian Li; Roger L Nation; Joseph A Nicolazzo
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

Review 6.  Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Authors:  R Deane; R D Bell; A Sagare; B V Zlokovic
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-03       Impact factor: 4.388

7.  Clearance and binding of two electrophoretic "fast" forms of human alpha 2-macroglobulin.

Authors:  M J Imber; S V Pizzo
Journal:  J Biol Chem       Date:  1981-08-10       Impact factor: 5.157

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

Authors:  Boris Hansel; Philippe Giral; Estelle Nobecourt; Sandrine Chantepie; Eric Bruckert; M John Chapman; Anatol Kontush
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  36 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

Review 2.  Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium.

Authors:  Livius V d'Uscio; Tongrong He; Zvonimir S Katusic
Journal:  Physiology (Bethesda)       Date:  2017-01

Review 3.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

4.  Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine.

Authors:  Fanuel T Hagos; Monica J Daood; Jacob A Ocque; Thomas D Nolin; Hulya Bayir; Samuel M Poloyac; Patrick M Kochanek; Robert S B Clark; Philip E Empey
Journal:  Xenobiotica       Date:  2016-06-09       Impact factor: 1.908

Review 5.  Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?

Authors:  Antoine Louveau; Sandro Da Mesquita; Jonathan Kipnis
Journal:  Neuron       Date:  2016-09-07       Impact factor: 17.173

Review 6.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

Review 7.  Peroxisome proliferator-activated receptors and Alzheimer's disease: hitting the blood-brain barrier.

Authors:  Juan M Zolezzi; Nibaldo C Inestrosa
Journal:  Mol Neurobiol       Date:  2013-03-14       Impact factor: 5.590

8.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice.

Authors:  Susan A Farr; Michelle A Erickson; Michael L Niehoff; William A Banks; John E Morley
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 9.  Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease.

Authors:  Michelle A Erickson; William A Banks
Journal:  J Cereb Blood Flow Metab       Date:  2013-08-07       Impact factor: 6.200

10.  Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease.

Authors:  Leslie Matalonga; Angela Arias; María Josep Coll; Judit Garcia-Villoria; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2013-12-18       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.